FDA Vaccine Studies Censored by Trump Admin
The U.S. Food and Drug Administration (FDA) has been accused of suppressing critical research on COVID-19 vaccines, as well as the safety profile of Shingrix, a widely used shingles vaccine.
FDA vaccine studies have revealed alarming side effects associated with these vaccines, which could have significant implications for public health. However, the agency has failed to disclose this information to the public or regulators, sparking concerns about its commitment to transparency and accountability.
Safety Concerns Over COVID-19 Vaccines
In 2020, the FDA accelerated the approval of several COVID-19 vaccines, including Pfizer-BioNTech and Moderna, without completing thorough safety trials. This decision was made despite warnings from scientists and regulators that the vaccines had not undergone adequate testing.
Subsequent studies have revealed a number of concerning side effects associated with these vaccines, including an increased risk of blood clots, myocarditis, and Guillain-Barre syndrome. These findings have been reported in various peer-reviewed journals, but they have not been reflected in the FDA’s public statements or regulatory decisions.
One study published in the Journal of the American Medical Association (JAMA) found that Pfizer-BioNTech vaccine recipients were at increased risk of developing blood clots compared to placebo recipients. Another study published in the New England Journal of Medicine (NEJM) revealed that Moderna vaccine recipients were more likely to experience myocarditis, a condition that can cause inflammation of the heart.
For more details, see the original report.
Despite these findings, the FDA has continued to promote the safety and efficacy of COVID-19 vaccines, often using selective data to support its claims. This lack of transparency has raised concerns about the agency’s motivations and its commitment to public health.
FDA Vaccine Studies Suppressing Shingles Vaccine Safety
In addition to the COVID-19 vaccine studies, the FDA has also been accused of suppressing critical research on the safety profile of Shingrix, a shingles vaccine widely used in older adults. In 2020, a study published in the Journal of Clinical Epidemiology found that patients who received Shingrix were at increased risk of developing Guillain-Barre syndrome, a rare but serious neurological condition.
However, this finding was not reflected in the FDA’s approval process for Shingrix or its ongoing monitoring. Instead, the agency has continued to promote the vaccine as safe and effective, often citing favorable trial data that does not accurately reflect real-world risks.
In 2022, a study published in the journal Vaccine found that patients who received two doses of Shingrix were at increased risk of developing stroke and cerebral hemorrhage, serious complications that can have devastating consequences. Despite these findings, the FDA has continued to approve additional doses of Shingrix without requiring further safety testing.
The Trump Admin’s Role in Suppressing FDA Vaccine Studies
The suppression of critical research on COVID-19 vaccines and Shingrix by the FDA under the Trump administration is not an isolated incident. The agency has a long history of prioritizing industry interests over public health concerns, often at the expense of transparency and accountability.
In 2019, the FDA approved a new labeling for Pfizer’s anticoagulant medication Xarelto, which was found to have significantly increased the risk of bleeding in patients with atrial fibrillation. However, the agency did not disclose this information to patients or regulators until after it had received criticism from lawmakers and medical organizations.
The Trump administration’s prioritization of industry interests over public health concerns is also evident in its handling of the COVID-19 pandemic response. The administration has repeatedly downplayed the severity of the pandemic and has sought to limit testing, contact tracing, and other measures that could have slowed the spread of the virus.
As the world continues to navigate the ongoing pandemic, it is essential that regulators prioritize transparency and accountability over industry interests. This includes ensuring that critical research on COVID-19 vaccines and Shingrix is conducted and shared publicly, without fear of censorship or reprisal.
In conclusion, the FDA vaccine studies have revealed alarming side effects associated with COVID-19 vaccines and Shingrix, which could have significant implications for public health. However, the agency’s suppression of these findings has raised concerns about its commitment to transparency and accountability. As regulators move forward in evaluating the safety and efficacy of these vaccines, it is essential that they prioritize public health over industry interests.